TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24946635
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (tamsulosin hydrochloride 0.2 mg once daily, indometacin 75 mg once daily)
Study: 22325459
Drug: Finasteride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (1 mg/d)
Study: 20849659
Drug: Multispecies probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multispecies probiotic intervention consisting of Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium breve Bb99
Study: 7653442
Drug: Nicorandil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (10 mg oral administration)
Study: 2572631
Drug: Glycol-poly-siloxane gel
Normalized name: glycolate Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycol-poly-siloxane gel
Study: 2572631
Drug: Weekly MRSA
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly MRSA colonization rate in neonates
Study: 31307434
Drug: CHIP lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHIP lifestyle intervention programme (12 weeks) followed by 9 months of monthly follow-up appointments
Study: 9308510
Drug: Metaproterenol sulfate
Normalized name: Metaproterenol Sulfate
DrugBank: Orciprenaline (DB00816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metaproterenol sulfate (1.3 mg, 2 inhalations every 4 hours while awake for 1 week)
Study: 3732093
Drug: Chlorthalidone (25‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (25‐50 mg daily)
Study: 26716656
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of encapsulated Cassia cinnamon bark (CASS)
Study: 26716656
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of encapsulated placebo (PLC)
Study: 22735863
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (5 g/day for six months)
Study: 22735863
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 g/day of maltodextrin for six months)
Study: 19262361
Drug: Optimal standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal standard heart failure therapy
Study: 9231199
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of DEC
Study: 8330600
Drug: subarachnoid bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: subarachnoid bupivacaine plus epidural morphine and bupivacaine
Study: 8330600
Drug: subarachnoid bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: subarachnoid bupivacaine plus intravenous midazolam and buprenorphine
Study: 8330600
Drug: epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: epidural bupivacaine plus epidural morphine
Study: 3033040
Drug: Local antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local antimicrobial prophylaxis (50 mg of polymyxin B, 80 mg of gentamicin, 300 mg of amphotericin B)
Study: 25986159
Drug: Formulated honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulated honey (53.5 g daily for 40 days)
Study: 25509258
Drug: Compound Qizhu
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Qizhu Granule (CQG) plus Lamivudin (LAM) and Adefovir (ADV)
Study: 16178481
Drug: 2% mupirocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% mupirocin cream applied daily to the exit site
Study: 8853261
Drug: Pancrease HL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancrease HL (25,000 units of lipase per capsule, 3 capsules/day)
Study: 8853261
Drug: Creon (8000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creon (8000 units of lipase per capsule, 9 capsules/day)
Study: 8853261
Drug: Pancrease HL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancrease HL with omeprazole (20 mg/day)
Study: 8853261
Drug: Creon with
Normalized name: Creon
DrugBank: Pancrelipase lipase (DB13147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creon with omeprazole (20 mg/day)
Study: 1737543
Drug: Insulin dose
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin dose minimization
Study: 30920584
Drug: Intra-procedural only
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intra-procedural only bivalirudin infusion
Study: 27283364
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (SB) 500 mg/day for 5 days
Study: 18835953
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (n = 19,326)
Study: 17786067
Drug: Nebivolol 1.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 1.25, 2.5, 5, 10, 20, or 40 mg once daily for up to 84 days
Study: 14638340
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy regimen including amoxicillin and clarithromycin with omeprazole, lansoprazole, or rabeprazole
Study: 10826574
Drug: Transcervical intrauterine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcervical intrauterine instillation of 5 mL of 2% lignocaine
Study: 8865110
Drug: Dipeptide-containing solution
Normalized name: palmitoyl dipeptide-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipeptide-containing solution (glycyl-glutamine/glycyl-tyrosine) infused at 0.60 mL/h/kg; 82.2 mg total dipeptides/amino acids/h/kg
Study: 8865110
Drug: Conventional amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional amino acid solutions infused at 0.73 mL/h/kg; 83.2 mg total amino acids/h/kg
Study: 2272187
Drug: Controlled-release indomethacin
Normalized name: indomethacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release indomethacin (75 mg)
Study: 19430350
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of losartan and nebivolol
Study: 16963731
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 or 500 mg/d)
Study: 16831672
Drug: Steroid (71
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid (71 patients)
Study: 30259769
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 1% lidocaine
Study: 30259769
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 2% lidocaine
Study: 8840367
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers, digoxin, and beta-blockers (specific dosages and duration not provided)
Study: 6133056
Drug: Single-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose therapy with chloroquine (10 mg base/kg)
Study: 6133056
Drug: Standard therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapeutic regimen of chloroquine (25 mg base/kg)
Study: 22609423
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (100 cc, three times a week for 1 year)
Study: 18172906
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg/day)
Study: 12211219
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg) with aspirin (325 mg)
Study: 12211219
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with aspirin (325 mg)
Study: 8720887
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg for induction, 5-6 mg/kg.h for maintenance
Study: 1917320
Drug: Topical isosorbide-mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical isosorbide-mononitrate (ISMO) 0.5% eye drops
Study: 1917320
Drug: Topical isosorbide-mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical isosorbide-mononitrate (ISMO) 2% eye drops
Study: 31892336
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor (AI) therapy for 2 weeks
Study: 31892336
Drug: No presurgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No presurgical treatment (control)
Study: 29319719
Drug: Low-cost negative-pressure
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-cost negative-pressure wound therapy (USP)
Study: 29319719
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available therapy device (VAC)
Study: 23612436
Drug: Methylphenidate (Ritalin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (Ritalin, 20 mg)
Study: 17053854
Drug: Peer norms
Normalized name: Worm Protector 2X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer norms supporting safe injection
Study: 9883955
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy programme
Study: 9100427
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) at doses of 5 mg, 10 mg, 15 mg, and 20 mg
Study: 2492893
Drug: Etidronate disodium
Normalized name: Etidronate Disodium
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etidronate disodium 400 mg daily for 3 months
Study: 2492893
Drug: Etidronate disodium
Normalized name: Etidronate Disodium
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etidronate disodium (after stopping therapy)
Study: 4851464
Drug: Intranasal DDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal DDAVP (twice-daily)
Study: 4851464
Drug: Intramuscular DDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular DDAVP (single daily injections)
Study: 25254570
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment control (just self-massage)
Study: 23341486
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate at 2 g/d (n = 174)
Study: 18289898
Drug: Brinzolamide suspension,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brinzolamide suspension, 1%, dosed twice daily
Study: 18289898
Drug: Levobetaxolol suspension,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobetaxolol suspension, 0.5%, dosed twice daily
Study: 1394814
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy consisting of monthly instillations of mitomycin C and doxorubicin for 12 months
Study: 1394814
Drug: Intravesical combination
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical combination chemotherapy (mitomycin C and doxorubicin)
Study: 27126154
Drug: Oral nutrition
Normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutrition supplements (ONS)
Study: 24953578
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc sulfate (10 mg/d)
Study: 20977764
Drug: Extracorporeal focused
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal focused shock wave therapy (2000 impulses, 0.25 mJ/m2 every 1-2 weeks) plus specific gluteal strength exercise training
Study: 20977764
Drug: Sham extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham extracorporeal focused shock wave therapy (2000 impulses, 0.01 mJ/m2 every 1-2 weeks) plus specific gluteal strength exercise training
Study: 18927173
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg daily) plus antioxidant capsule
Study: 18927173
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg daily) plus placebo capsule
Study: 18927173
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet plus antioxidant capsule
Study: 18927173
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet plus placebo capsule
Study: 9708873
Drug: Dietary intake
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intake of fresh fruit (g/day)
Study: 9708873
Drug: Dietary vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary vitamin C intake (mg/day) measured by DR
Study: 9708873
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of vitamin C supplements
Study: 7635771
Drug: Overall Treatment
Normalized name: Healthy Kids Overall Health Gummies Soft Chew
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall Treatment Time (OTT)
Study: 2359302
Drug: Couples group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couples group therapy condition
Study: 2359302
Drug: Standard individual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard individual therapy condition
Study: 30131583
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment (exact dosage not specified)
Study: 26787505
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) 4 mg/kg
Study: 22039165
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of biomarkers
Study: 12583554
Drug: Amoxicillin‐clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanic acid (2.2 g)
Study: 15724911
Drug: Incidental encoding
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incidental encoding of temporal context; no specific dosage or duration mentioned.
Study: 15724911
Drug: Intentional encoding
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intentional encoding of temporal context; no specific dosage or duration mentioned.
Study: 15724911
Drug: Retrieval of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrieval of encoding context as a cue for list occurrence; no specific dosage or duration mentioned.
Study: 15724911
Drug: Evaluating temporal
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluating temporal distance from the strength of the memory trace; no specific dosage or duration mentioned.
Study: 10402402
Drug: In-house Earle's
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-house Earle's balanced salt solution (EBSS)
Study: 10402402
Drug: Commercially prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially prepared Earle's balanced salt solution (EBSS)
Study: 7720336
Drug: L-arginine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (0.1 g/kg)
Study: 7720336
Drug: L-arginine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (0.2 g/kg)
Study: 2035794
Drug: Subcutaneous wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous wound infiltration with 20 ml of 0.5% bupivacaine
Study: 7034564
Drug: Quinine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine plus a single dose of pyrimethamine‐sulfadoxine (Fansidar)
Study: 31931923
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (benzocaine gel) without audiovisual distraction (AVD)
Study: 30040008
Drug: Vestibular Rehabilitation
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular Rehabilitation Therapy (VRT) in conjunction with cervical spine therapy
Study: 30040008
Drug: Vestibular Rehabilitation
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular Rehabilitation Therapy (VRT)
Study: 30040008
Drug: Vestibular Rehabilitation
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular Rehabilitation Therapy (VRT) in conjunction with light aerobic exercise
Study: 30040008
Drug: Cervical spine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical spine therapy alone
Study: 25413267
Drug: Ropivacaine 0.4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.4% infusion
Study: 22795925
Drug: Ipragliflozin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin (300 mg qd)
Study: 21165291
Drug: Overall Treatment
Normalized name: Healthy Kids Overall Health Gummies Soft Chew
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall Treatment Effect (OTE) for EC‐MPS
Study: 12403858
Drug: Home-based asthma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based asthma education program (8 weekly sessions)
Study: 10547391
Drug: Fenretinide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenretinide (200 mg/day for 5 years)
Study: 2179478
Drug: Bacillus Calmette‐Guérin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette‐Guérin (BCG) therapy administered in weekly scarifications up to 3 years
Study: 3047335
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy (Control group)
Study: 2179478
Drug: Bacillus Calmette‐Guérin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette‐Guérin (BCG) therapy
Study: 7471341
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg buccally)
Study: 30391194
Drug: Oral selexipag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral selexipag
Study: 27764781
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by IV cisplatin and vinorelbine chemotherapy
Study: 25873050
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron treatment at 6 mg/kg/day plus dietary advice
Study: 23564916
Drug: n-3FA supplement
Normalized name: (+/-)-N-methylephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3FA supplement
Study: 18506446
Drug: Low-dose 40
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose 40 mg Depo-Medrol soaked Gelfoam applied over the affected nerve root after discectomy
Study: 16813586
Drug: Combination pre-operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination pre-operative chemoradiotherapy (CRT)
Study: 8832772
Drug: ORG-2766 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG-2766 (40 mg/day)
Study: 29978378
Drug: RBE-enriched porridge
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBE-enriched porridge (35 g, including 2 g RBE) with water
Study: 29978378
Drug: RBE-enriched porridge
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBE-enriched porridge (35 g, including 2 g RBE) with milk
Study: 29978378
Drug: RBE oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBE oil (2 g)
Study: 25348594
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment options (endoscopic fundoplication and PPI therapy)
Study: 23059790
Drug: Intrathecal methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal methylprednisolone acetate (MPA) 60 mg + lidocaine 60 mg
Study: 23059790
Drug: Lidocaine 60
Normalized name: Gabapentin;Lidocaine 600 MG; 5% Multiple Routes Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 60 mg only (Control)
Study: 22093120
Drug: Dornase alpha
Normalized name: Dornase alpha
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dornase alpha inhaled after airway clearance techniques
Study: 22093120
Drug: Dornase alpha
Normalized name: Dornase alpha
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dornase alpha inhaled before airway clearance techniques
Study: 9166128
Drug: 10 mg/m3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/m3 NMP
Study: 9166128
Drug: 25 mg/m3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/m3 NMP
Study: 9166128
Drug: 50 mg/m3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m3 NMP
Study: 7702974
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine (5 micrograms/kg/min) and isosorbide dinitrate (2 micrograms/kg/min) gated blood pool scintigraphy (GBPS)
Study: 3312176
Drug: Fluoxetine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (all doses)
Study: 26359996
Drug: IncobotulinumtoxinA (54
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncobotulinumtoxinA (54 to 64 U administered: GFL 20 U; HFL 10-20 U; LPL 24 U)
Study: 14583744
Drug: CBD (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (400 mg)
Study: 18571340
Drug: Psychosocial therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial therapies
Study: 15494910
Drug: Single 500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 500-mg dose of azithromycin
Study: 15494910
Drug: 1-week course
Normalized name: ESTRADIOL BENZOATE 1 kg in 1 kg POWDER [Estradiol Benzoate Coarse Grade]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week course of daily 200-mg dose of doxycycline
Study: 11032403
Drug: Twice-a-day IFN-beta
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-a-day IFN-beta injection (3 MU i.v. twice a day for 2 weeks)
Study: 11032403
Drug: Once-a-day IFN-beta
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-a-day IFN-beta injection (6 MU daily)